Following NICE's announcement last week regarding Trodelvy, what is the latest with regards to making it available to cancer patients in Wales on the NHS?
Answered by Minister for Health and Social Services | Answered on 01/08/2022
NICE published its final appraisal document recommending the use of Sacituzumab govitecan (Trodelvy®) for treating unresectable triple-negative advanced breast cancer after two or more previous therapies on 14 July. In accordance with the requirements of the New Treatment Fund, health boards must make Trodelvy® routinely available within two months.